Evidence for sequence selection within the non-structural 5A gene of hepatitis C virus type 1b during unsuccessful treatment with interferon-α

被引:22
作者
Gerotto, M
Dal Pero, F
Sullivan, DG
Chemello, L
Cavalletto, L
Polyak, SJ
Pontisso, P
Gretch, DR
Alberti, A
机构
[1] Univ Padua, Dept Clin & Expt Med, I-35128 Padua, Italy
[2] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA
[3] Univ Washington, Dept Med, Seattle, WA USA
关键词
clonal frequency analysis; HCV infection; IFN resistance; NS5A-ISDR;
D O I
10.1046/j.1365-2893.1999.00166.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Resistance of the hepatitis C virus (HCV) to interferon-alpha (IFN-alpha) therapy in patients with hepatitis C maybe genetically controlled by an IFN sensitivity-determining region (ISDR) within the non-structural 5A (NS5A) gene. To assess whether HCV 1b strains carrying a 'resistant' type of ISDR are selected during unsuccessful IFN therapy, we analysed the evolution of the NS5A quasispecies, as detected by the clonal frequency analysis technique, and of the ISDR sequence by nucleotide sequence determination, in 11 patients showing no virological response during two consecutive cycles of IFN-alpha therapy, IFN-resistant patients had a homogeneous ISDR quasispecies with sequences identical to those described as resistant-' or 'intermediate-' type ISDR, After retreatment with IFN, further selection towards a homogeneous viral population was observed and 10 out of 11 patients had only one variant of HCV with no or just one single amino acid mutation within the ISDR sequence, Treatment and retreatment with IFN was associated in our nonresponder patients with evolution of the ISDR quasispecies towards a rather homogeneous viral population carrying a conserved or minimally mutated ISDR motif, supporting the idea that this motif may be relevant for IFN resistance in HCV 1b-infected individuals.
引用
收藏
页码:367 / 372
页数:6
相关论文
共 19 条
[1]   THE NATURAL-HISTORY OF COMMUNITY-ACQUIRED HEPATITIS-C IN THE UNITED-STATES [J].
ALTER, MJ ;
MARGOLIS, HS ;
KRAWCZYNSKI, K ;
JUDSON, FN ;
MARES, A ;
ALEXANDER, WJ ;
HU, PY ;
MILLER, JK ;
GERBER, MA ;
SAMPLINER, RE ;
MEEKS, EL ;
BEACH, MJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (27) :1899-1905
[2]   Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection [J].
Chayama, K ;
Tsubota, A ;
Kobayashi, M ;
Okamoto, K ;
Hashimoto, M ;
Miyano, Y ;
Koike, H ;
Kobayashi, M ;
Koida, I ;
Arase, Y ;
Saitoh, S ;
Suzuki, Y ;
Murashima, N ;
Ikeda, K ;
Kumada, H .
HEPATOLOGY, 1997, 25 (03) :745-749
[3]  
CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
[4]   Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C [J].
Davis, GL ;
Esteban-Mur, R ;
Rustgi, V ;
Hoefs, J ;
Gordon, SC ;
Trepo, C ;
Shiffman, ML ;
Zeuzem, S ;
Craxi, A ;
Ling, MH ;
Albrecht, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (21) :1493-1499
[5]  
ENAMOTO N, 1995, J CLIN INVEST, V96, P224
[6]  
ENAMOTO N, 1996, NEW ENGL J MED, V334, P77
[7]   Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein [J].
Gale, MJ ;
Korth, MJ ;
Tang, NM ;
Tan, SL ;
Hopkins, DA ;
Dever, TE ;
Polyak, SJ ;
Gretch, DR ;
Katze, MG .
VIROLOGY, 1997, 230 (02) :217-227
[8]  
GRETCH DR, 1995, HEPATOLOGY, V22, P1
[9]  
*HEP BRANCH CTR DI, 1997, 1997 HEP C FACT SHEE
[10]   The treatment of chronic viral hepatitis [J].
Hoofnagle, JH ;
DiBisceglie, AM .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (05) :347-356